Pfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.
Follow PFE
Pfizer Inc. 10-K filed Feb 26, 2026
What changed
Item 7, Management’s Discussion and Analysis, against the 10-K filed Feb 27, 2025: 39 added · 50 removed · 71 modified; 31 with only figures updated; 1 moved without change
160 more changes in this Item, word by word, in Powerpack.
Powerpack